OH-CAS
CAS, a division of the American Chemical Society specializing in scientific information solutions, announced several initiatives to once again transform scientific research, and empower more rapid discovery for life sciences innovation.
CAS is expanding its comprehensive, highly structured, human-curated scientific data with the introduction of life sciences assets. The CAS Content CollectionTM now includes exhaustive biological sequences and bioactivity information designed to accelerate early-stage drug discovery research, with future additions including antibodies, omics, and more.
CAS is collaborating with Chemotargets to leverage Clarity® to serve as its technology foundation for rapid development, with future investments driving integration and expansion to cover the end-to-end pharmaceutical R&D workflow and accelerate therapeutic innovation.
“Unique insights derived from combining high-quality, comprehensive CAS scientific data with new technologies will enable drug discovery scientists to efficiently analyze how a modification in molecular structure may change the effect or toxicity of a drug, to evaluate drug-target-disease relationships, to assess freedom to operate in an area, and ultimately to design better, safer drugs with less financial risk,” said Manuel Guzman, President, CAS. “Our goal is to empower every aspect of drug discovery across scientific disciplines, including biology, and this expansion reflects a historic milestone on our path to accelerate life sciences research.”
CAS recently established a Life Sciences Industry Advisory Board comprising a world-class panel of global thought leaders from commercial, academic, and government organizations. These experts serve as trusted advisors, directing our scientific journey as we combine authoritative content with groundbreaking predictive technologies that span the spectrum of life sciences workflows. Under their advisement, CAS life sciences investments will continue, with focused content and capabilities to drive better decisions early in the drug discovery process… from understanding disease progression with its comprehensive biological pathway data to assessing the effectiveness of investigational drugs with enriched molecular biomarker data.
“Our enhanced capabilities, including predictive pharmacology tools and analytical visualization of drug-target-disease interactions, will be a leap forward for medicinal chemists and other drug discovery professionals,” according to Tim Wahlberg, Chief Product Officer, CAS. “Scientists will be able to leverage the most advanced relevance engine in the industry alongside new capabilities, not only to find inspiration for new ideas, but also to predict the viability and safety of drug candidates very early in the drug discovery process.”
About CAS
CAS is a leader in scientific information solutions, partnering with innovators around the world to accelerate scientific breakthroughs. CAS employs over 1,400 experts who curate, connect, and analyze scientific knowledge to reveal unseen connections. For over 100 years, scientists, patent professionals, and business leaders have relied on CAS solutions and expertise to provide the hindsight, insight, and foresight they need so they can build upon the learnings of the past to discover a better future. CAS is a division of the American Chemical Society. Connect with us at cas.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221215005465/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Estée Lauder Companies Announces Pricing of Secondary Offering of Class A Common Stock by Selling Stockholders5.11.2025 02:08:00 CET | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announces the pricing of the previously announced registered public offering (the “Offering”) of the Company’s Class A Common Stock, par value $.01 per share, by trusts affiliated with descendants of Leonard A. Lauder (the “Selling Stockholders”) at a price to the public of $90 per share. The Selling Stockholders will receive all of the proceeds from the Offering. The Company is not selling any shares of Class A Common Stock in the Offering and will not receive any proceeds from the Offering. The Offering is expected to close on November 6, 2025, subject to the satisfaction of customary closing conditions. The Selling Stockholders intend to use the proceeds of the Offering to assist with the settlement of Leonard A. Lauder’s estate, including to satisfy certain estate obligations such as estate taxes, debts and administration expenses. Based on shares outstanding as of October 23, 2025, following completion of the offering, members of th
The Earthshot Prize and 500 Global Announce Strategic Partnership to Advance Climate Innovation in Emerging Markets5.11.2025 01:01:00 CET | Press release
500 Global and The Earthshot Prize are partnering on an investment strategy to identify, support and scale climate solutions across Emerging Markets.Supporting three themes at the intersection of climate impact and commercial viability: AgTech, Clean Tech, and Nature Tech.The strategy was announced at The Earthshot Prize Summit in Rio De Janeiro ahead of the 2025 Earthshot Prize Awards Night, targeting to roll out H1 of 2026. 500 Global, one of the world’s most active venture capital firms and The Earthshot Prize, the world’s most prestigious and impactful environmental award, are announcing today a new strategic partnership to accelerate climate innovation in Emerging Markets, as climate finance is more relevant than ever before. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104586243/en/ 500 Global intends to develop and implement an investment strategy designed to de-risk early-stage investments, unlocking private cap
Cooler Master Announces the QUBE 540 PC Case, a Compact Size with Unlimited Creativity4.11.2025 23:58:00 CET | Press release
Designed for Creators, Gamers, and DIY Builders Cooler Master, a global leader in PC components and tech lifestyle solutions, today announced the QUBE 540, a compact case for today. The QUBE 540 offers orientation flexibility, so you can build a vertical or horizontal system that fits your desk or shelf. Inside, a modular interior lets you tailor the layout to your components and airflow preferences. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104224092/en/ The QUBE 540 (Stardust Iron) with 3D-printed additions holding headphones and keyboard. The QUBE 540 keeps the clean, geometric design language of the QUBE series while raising the bar on practical adaptability. It fits comfortably in limited spaces such as small apartments and dorm rooms, and it looks at home in creator studios and living areas. The case ships in two colors, Moonstone or Stardust Iron, giving users options that blend with modern setups and room aes
IFF Reports Third Quarter 2025 Results4.11.2025 23:12:00 CET | Press release
Reaffirms Full Year 2025 Financial Guidance IFF (NYSE: IFF) reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Consolidated Summary: Management Commentary “Our third quarter results demonstrate continued execution in a tough operating environment,” said Erik Fyrwald, CEO of IFF. “Sales momentum in Scent and Taste remain solid, supported by strong new win contributions. This performance helped offset short-term pressures in Health and Biosciences - which we are addressing by strengthening our innovation and commercial capabilities - and a sales reduction in Food Ingredients as we focus on driving higher margins.” “Profitability in the quarter improved high-single digits year-over-year, with margin expansion driven predominantly by productivity. By maintaining a disciplined focus on operational excellence, we are driving sustained profitability while investing in IFF for long-term success.” “In a more challenging environment, we’re doing what we
The Estée Lauder Companies Announces Secondary Offering of Class A Common Stock by Selling Stockholders4.11.2025 22:47:00 CET | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announces that trusts affiliated with descendants of Leonard A. Lauder (the “Selling Stockholders”) propose to sell 11,301,323 shares of the Company’s Class A Common Stock, par value $.01 per share, through a proposed registered public offering (the “Offering”). The Selling Stockholders will receive all of the proceeds from the Offering. The Company is not selling any shares of Class A Common Stock in the Offering and will not receive any proceeds from the Offering. The Selling Stockholders intend to use the proceeds of the Offering to assist with the settlement of Leonard A. Lauder’s estate, including to satisfy certain estate obligations such as estate taxes, debts and administration expenses. Based on shares outstanding as of October 23, 2025, following completion of the offering, members of the Lauder family will beneficially own, directly or indirectly, 82% of the outstanding voting power of the Company’s Common Stock. The Selling S
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom